TDMS Study 05110-02 Pathology Tables
NTP Experiment-Test: 05110-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 08/15/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:28:03
CORE STUDY RATS/FINAL#3
Facility: Battelle Northwest
Chemical CAS #: 91-20-3
Lock Date: 01/05/99
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05110-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 08/15/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:28:03
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 10 PPM 30 PPM 60 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 49 49 49 49
Early Deaths
Moribund Sacrifice 18 22 16 21
Natural Death 3 6 5 4
Survivors
Terminal Sacrifice 28 21 28 24
Animals Examined Microscopically 49 49 49 49
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (49) (49) (49) (49)
Intestine Small, Jejunum (49) (48) (48) (46)
Intestine Small, Ileum (49) (48) (47) (46)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Liver (49) (49) (49) (49)
Hepatocellular Carcinoma 1 (2%) 1 (2%)
Mesentery (13) (8) (7) (5)
Pancreas (49) (49) (49) (49)
Salivary Glands (49) (49) (49) (49)
Adenoma 1 (2%)
Stomach, Forestomach (49) (49) (49) (49)
Stomach, Glandular (49) (48) (49) (49)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Tongue (1) (1) (1)
Squamous Cell Papilloma 1 (100%)
Epithelium, Squamous Cell Papilloma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (49) (49) (49) (49)
Schwannoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05110-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 08/15/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:28:03
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 10 PPM 30 PPM 60 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (49) (49) (49)
Adenoma 1 (2%) 2 (4%) 1 (2%)
Adrenal Medulla (48) (49) (49) (49)
Pheochromocytoma Benign 2 (4%) 1 (2%) 2 (4%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (49) (49) (49) (49)
Adenoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Parathyroid Gland (42) (40) (41) (48)
Pituitary Gland (49) (49) (49) (48)
Pars Distalis, Adenoma 23 (47%) 27 (55%) 24 (49%) 20 (42%)
Pars Distalis, Carcinoma 1 (2%)
Thyroid Gland (47) (46) (48) (48)
Bilateral, C-Cell, Adenoma 1 (2%)
C-Cell, Adenoma 4 (9%) 3 (7%) 2 (4%) 1 (2%)
C-Cell, Carcinoma 3 (6%) 2 (4%) 2 (4%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (49) (47) (49) (48)
Adenoma 3 (6%) 7 (15%) 4 (8%) 2 (4%)
Carcinoma 1 (2%) 1 (2%) 1 (2%)
Bilateral, Adenoma 1 (2%)
Ovary (49) (49) (49) (49)
Granulosa Cell Tumor Malignant 2 (4%) 2 (4%)
Granulosa-Theca Tumor Malignant 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Uterus (49) (49) (49) (49)
Carcinoma 1 (2%)
Polyp Stromal 14 (29%) 5 (10%) 8 (16%) 7 (14%)
Bilateral, Polyp Stromal 1 (2%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05110-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 08/15/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:28:03
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 10 PPM 30 PPM 60 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (49) (49) (49)
Lymph Node (2) (3) (2) (3)
Lymph Node, Bronchial (42) (33) (34) (36)
Lymph Node, Mandibular (47) (39) (46) (47)
Lymph Node, Mesenteric (49) (49) (49) (49)
Lymph Node, Mediastinal (40) (39) (41) (31)
Spleen (49) (49) (49) (49)
Hemangiosarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Thymus (46) (45) (48) (41)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (49) (49) (49)
Carcinoma 3 (6%) 5 (10%) 3 (6%) 3 (6%)
Fibroadenoma 14 (29%) 16 (33%) 17 (35%) 10 (20%)
Fibroadenoma, Multiple 3 (6%) 4 (8%) 1 (2%) 4 (8%)
Skin (49) (49) (49) (49)
Basal Cell Adenoma 1 (2%)
Keratoacanthoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (49) (49) (49) (49)
Osteosarcoma 1 (2%)
Skeletal Muscle (2)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (49) (49) (49) (49)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Glioma Malignant 1 (2%)
Neuroblastoma, Metastatic, Nose 1 (2%) 4 (8%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05110-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 08/15/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:28:03
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 10 PPM 30 PPM 60 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (49) (49) (49) (49)
Lung (49) (49) (49) (49)
Alveolar/Bronchiolar Adenoma 1 (2%)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Nose (49) (49) (49) (49)
Olfactory Epithelium, Neuroblastoma 2 (4%) 3 (6%) 12 (24%)
Respiratory Epithelium, Adenoma 4 (8%) 2 (4%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (2) (1)
Carcinoma 2 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (48) (49) (49) (49)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (48) (49) (49) (49)
Transitional Epithelium, Papilloma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(49) *(49) *(49) *(49)
Leukemia Mononuclear 16 (33%) 21 (43%) 15 (31%) 15 (31%)
Mesothelioma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05110-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 08/15/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:28:03
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 10 PPM 30 PPM 60 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 44 48 47 44
Total Primary Neoplasms 104 105 97 85
Total Animals with Benign Neoplasms 38 41 43 35
Total Benign Neoplasms 72 69 69 53
Total Animals with Malignant Neoplasms 26 34 26 27
Total Malignant Neoplasms 32 36 28 32
Total Animals with Metastatic Neoplasms 4 1 4
Total Metastatic Neoplasm 8 1 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05110-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 08/15/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:28:03
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 10 PPM 30 PPM 60 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 49 49 49 49
Early Deaths
Moribund Sacrifice 21 22 19 25
Natural Death 4 5 6 3
Survivors
Terminal Sacrifice 24 22 23 21
Other 1
Animals Examined Microscopically 49 49 48 49
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (48) (49) (48) (48)
Polyp Adenomatous 1 (2%)
Intestine Large, Cecum (46) (49) (47) (48)
Intestine Small, Jejunum (45) (47) (43) (47)
Carcinoma 1 (2%)
Leiomyosarcoma 1 (2%)
Intestine Small, Ileum (45) (47) (45) (47)
Liver (49) (49) (48) (49)
Hepatocellular Carcinoma 1 (2%) 1 (2%)
Hepatocellular Adenoma 1 (2%) 3 (6%)
Mesentery (13) (6) (9) (8)
Hemangiosarcoma 1 (13%)
Sarcoma 1 (8%)
Pancreas (49) (49) (48) (49)
Adenoma 1 (2%) 2 (4%)
Carcinoma 1 (2%)
Mixed Tumor Benign 1 (2%)
Salivary Glands (49) (49) (47) (49)
Stomach, Forestomach (49) (49) (48) (49)
Stomach, Glandular (49) (49) (48) (49)
Tongue (1) (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05110-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 08/15/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:28:03
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 10 PPM 30 PPM 60 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (49) (49) (48) (49)
Schwannoma Benign 1 (2%) 2 (4%)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (49) (48) (49)
Adenoma 2 (4%) 1 (2%) 2 (4%)
Adrenal Medulla (49) (49) (47) (49)
Pheochromocytoma Malignant 1 (2%) 3 (6%) 1 (2%) 1 (2%)
Pheochromocytoma Benign 4 (8%) 6 (12%) 6 (13%) 8 (16%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (49) (49) (48) (49)
Adenoma 2 (4%) 5 (10%) 3 (6%) 2 (4%)
Carcinoma 4 (8%) 4 (8%) 4 (8%) 4 (8%)
Pituitary Gland (49) (49) (47) (49)
Pars Distalis, Adenoma 31 (63%) 31 (63%) 35 (74%) 29 (59%)
Thyroid Gland (46) (47) (45) (47)
Bilateral, C-Cell, Adenoma 1 (2%)
C-Cell, Adenoma 9 (20%) 5 (11%) 4 (9%) 4 (9%)
C-Cell, Carcinoma 1 (2%) 2 (4%) 1 (2%) 1 (2%)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
Pheochromocytoma Malignant, Metastatic,
Adrenal Medulla 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (49) (48) (49)
Preputial Gland (48) (49) (47) (49)
Adenoma 3 (6%) 1 (2%) 1 (2%)
Carcinoma 3 (6%) 1 (2%) 1 (2%) 1 (2%)
Prostate (49) (49) (48) (49)
Seminal Vesicle (47) (49) (47) (47)
Carcinoma 1 (2%)
Page 8
NTP Experiment-Test: 05110-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 08/15/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:28:03
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 10 PPM 30 PPM 60 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Testes (49) (49) (48) (49)
Bilateral, Interstitial Cell, Adenoma 24 (49%) 22 (45%) 19 (40%) 20 (41%)
Interstitial Cell, Adenoma 14 (29%) 10 (20%) 17 (35%) 11 (22%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (49) (48) (49)
Lymph Node (3) (3) (8) (4)
Lymph Node, Bronchial (29) (36) (38) (35)
Lymph Node, Mandibular (40) (45) (46) (44)
Lymph Node, Mesenteric (47) (49) (48) (49)
Lymph Node, Mediastinal (24) (28) (44) (41)
Spleen (49) (49) (48) (49)
Hemangiosarcoma 1 (2%) 1 (2%)
Thymus (47) (46) (43) (46)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (21) (20) (30) (28)
Carcinoma 1 (5%) 1 (5%) 1 (3%)
Fibroadenoma 3 (11%)
Skin (48) (48) (48) (48)
Basal Cell Adenoma 1 (2%) 2 (4%)
Keratoacanthoma 4 (8%) 3 (6%) 2 (4%) 2 (4%)
Squamous Cell Carcinoma 1 (2%)
Sebaceous Gland, Adenoma 1 (2%) 1 (2%) 1 (2%)
Sebaceous Gland, Carcinoma 1 (2%)
Subcutaneous Tissue, Fibroma 5 (10%) 2 (4%) 2 (4%) 2 (4%)
Subcutaneous Tissue, Fibrosarcoma 2 (4%) 1 (2%) 2 (4%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%) 1 (2%) 3 (6%)
Subcutaneous Tissue, Neural Crest Tumor 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 2 (4%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05110-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 08/15/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:28:03
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 10 PPM 30 PPM 60 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (49) (49) (48) (49)
Osteosarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (49) (49) (48) (49)
Neuroblastoma, Metastatic, Nose 2 (4%)
Spinal Cord (1)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (49) (49) (48) (49)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Lung (49) (49) (48) (49)
Alveolar/Bronchiolar Adenoma 2 (4%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 3 (6%)
Carcinoma, Metastatic, Preputial Gland 1 (2%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%) 1 (2%)
Neuroblastoma, Metastatic, Nose 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%) 1 (2%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Medulla 1 (2%) 1 (2%) 1 (2%)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Nose (49) (49) (48) (48)
Olfactory Epithelium, Neuroblastoma 4 (8%) 3 (6%)
Respiratory Epithelium, Adenoma 6 (12%) 8 (17%) 15 (31%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (48) (48) (48) (48)
Zymbal's Gland (1) (1)
Carcinoma 1 (100%)
Bilateral, Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05110-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 08/15/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:28:03
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 10 PPM 30 PPM 60 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (49) (48) (49)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Transitional Epithelium, Carcinoma 1 (2%)
Urinary Bladder (48) (49) (48) (49)
Transitional Epithelium, Papilloma 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(49) *(49) *(48) *(49)
Leukemia Mononuclear 26 (53%) 21 (43%) 24 (50%) 17 (35%)
Mesothelioma Benign 2 (4%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05110-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 08/15/00
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 08:28:03
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 10 PPM 30 PPM 60 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 48 49 48 49
Total Primary Neoplasms 149 139 152 146
Total Animals with Benign Neoplasms 46 47 47 47
Total Benign Neoplasms 107 96 110 108
Total Animals with Malignant Neoplasms 34 32 34 32
Total Malignant Neoplasms 42 43 42 37
Total Animals with Metastatic Neoplasms 4 3 4 3
Total Metastatic Neoplasm 4 3 8 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------